SCHEMBL19989450

SCHEMBL19989450

COc1c(B2OC(C)(C)C(C)(C)O2)ccc2[nH]nc(N)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 3/20 0.34
GAA P10253 1/20 0.34
MAP2K1 Q02750 2/20 0.32
ROCK1 Q13464 4/20 0.32
AURKA O14965 2/20 0.32
AURKB Q96GD4 2/20 0.32
TGFBR1 P36897 1/20 0.32
KDR P35968 4/20 0.31
KIT P10721 1/20 0.31
FLT3 P36888 1/20 0.31
CDK5 Q00535 2/20 0.30
CLK4 Q9HAZ1 2/20 0.30
CDK8 P49336 1/20 0.30
LCK P06239 2/20 0.30
CSF1R P07333 2/20 0.30
FGFR1 P11362 2/20 0.30
PRKACA P17612 2/20 0.30
PLK4 O00444 1/20 0.30
JAK2 O60674 1/20 0.30
CDK1 P06493 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859572 1.00 PDPK1 (0.34) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL19989510 0.82 PDPK1 (0.36) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL29859433 0.82 PDPK1 (0.36) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL19989547 0.82 GAA (0.43) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL29859216 0.82 GAA (0.43) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL29859747 0.81 KDR (0.37) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL19989468 0.81 KDR (0.37) PDPK1GAAMAP2K1ROCK1AURKA
SCHEMBL19989528 0.76 KDM4E (0.35) KDRKITFLT3
SCHEMBL29859422 0.76 KDM4E (0.35) KDRKITFLT3
SCHEMBL29712207 0.73 BRD4 (0.39) ROCK1FLT3ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 PDPK1 1841/4885GAA 4269/4885MAP2K1 2416/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 PDPK1 1649/4885GAA 3844/4885MAP2K1 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.